Cargando…

Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey

BACKGROUND: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Budzyński, Jacek, Pulkowski, Grzegorz, Suppan, Karol, Fabisiak, Jacek, Majer, Marcin, Kłopocka, Maria, Galus-Pulkowska, Beata, Wasielewski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186737/
https://www.ncbi.nlm.nih.gov/pubmed/21939510
http://dx.doi.org/10.1186/1477-7525-9-77
_version_ 1782213292942426112
author Budzyński, Jacek
Pulkowski, Grzegorz
Suppan, Karol
Fabisiak, Jacek
Majer, Marcin
Kłopocka, Maria
Galus-Pulkowska, Beata
Wasielewski, Marcin
author_facet Budzyński, Jacek
Pulkowski, Grzegorz
Suppan, Karol
Fabisiak, Jacek
Majer, Marcin
Kłopocka, Maria
Galus-Pulkowska, Beata
Wasielewski, Marcin
author_sort Budzyński, Jacek
collection PubMed
description BACKGROUND: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The study addressed whether omeprazole treatment also affects general health-related quality of life (HRQL) in patients with CAD. STUDY: 48 patients with more than 50% narrowing of the coronary arteries on angiography without clinically overt gastrointestinal symptoms were studied. In a double-blind, placebo-controlled, cross-over study design, patients were randomized to take omeprazole 20 mg bid or a placebo for two weeks, and then crossed over to the other study arm. The SF-36 questionnaire was completed before treatment and again after two weeks of therapy. RESULTS: Patients treated with omeprazole in comparison to the subjects taking the placebo had significantly greater values for the SF-36 survey (which relates to both physical and mental health), as well as for bodily pain, general health perception, and physical health. In comparison to the baseline values, therapy with omeprazole led to a significant increase in the three summarized health components: total SF-36; physical and mental health; and in the following detailed health concept scores: physical functioning, limitations due to physical health problems, bodily pain and emotional well-being. CONCLUSIONS: A double dose of omeprazole improved the general HRQL in patients with CAD without severe gastrointestinal symptoms more effectively than the placebo.
format Online
Article
Text
id pubmed-3186737
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31867372011-10-05 Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey Budzyński, Jacek Pulkowski, Grzegorz Suppan, Karol Fabisiak, Jacek Majer, Marcin Kłopocka, Maria Galus-Pulkowska, Beata Wasielewski, Marcin Health Qual Life Outcomes Research BACKGROUND: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The study addressed whether omeprazole treatment also affects general health-related quality of life (HRQL) in patients with CAD. STUDY: 48 patients with more than 50% narrowing of the coronary arteries on angiography without clinically overt gastrointestinal symptoms were studied. In a double-blind, placebo-controlled, cross-over study design, patients were randomized to take omeprazole 20 mg bid or a placebo for two weeks, and then crossed over to the other study arm. The SF-36 questionnaire was completed before treatment and again after two weeks of therapy. RESULTS: Patients treated with omeprazole in comparison to the subjects taking the placebo had significantly greater values for the SF-36 survey (which relates to both physical and mental health), as well as for bodily pain, general health perception, and physical health. In comparison to the baseline values, therapy with omeprazole led to a significant increase in the three summarized health components: total SF-36; physical and mental health; and in the following detailed health concept scores: physical functioning, limitations due to physical health problems, bodily pain and emotional well-being. CONCLUSIONS: A double dose of omeprazole improved the general HRQL in patients with CAD without severe gastrointestinal symptoms more effectively than the placebo. BioMed Central 2011-09-22 /pmc/articles/PMC3186737/ /pubmed/21939510 http://dx.doi.org/10.1186/1477-7525-9-77 Text en Copyright ©2011 Budzyński et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Budzyński, Jacek
Pulkowski, Grzegorz
Suppan, Karol
Fabisiak, Jacek
Majer, Marcin
Kłopocka, Maria
Galus-Pulkowska, Beata
Wasielewski, Marcin
Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
title Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
title_full Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
title_fullStr Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
title_full_unstemmed Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
title_short Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
title_sort improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. a double-blind, placebo-controlled trial of the sf-36 survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186737/
https://www.ncbi.nlm.nih.gov/pubmed/21939510
http://dx.doi.org/10.1186/1477-7525-9-77
work_keys_str_mv AT budzynskijacek improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT pulkowskigrzegorz improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT suppankarol improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT fabisiakjacek improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT majermarcin improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT kłopockamaria improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT galuspulkowskabeata improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey
AT wasielewskimarcin improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey